PZ0383
帕博昔利
≥98% (HPLC), powder, CDK 4 & 6 inhibitor
别名:
6-乙酰基-8-环戊基-5-甲基-2-[[[5-（1-哌嗪基）-2-吡啶基]氨基]吡啶基[2,3-d]嘧啶-7（8H）-酮, PD 0332991, PD 332991, PD-0332991, PD0332991, PD991, PF 00080665, PF-00080665, PF00080665, 爱博新
产品名称
帕博昔利, ≥98% (HPLC)
SMILES string
CC(C1=C(N2C3CCCC3)N=C(NC4=CC=C(N5CCNCC5)C=N4)N=C1)=C(C(C)=O)C2=O
InChI
1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)
InChI key
AHJRHEGDXFFMBM-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
0.1 M HCl: 2 mg/mL, clear
storage temp.
room temp
Biochem/physiol Actions
PF-00080665（Palbociclib；PD 0332991）是一种靶向周期蛋白依赖性激酶4&6（使用CDK4/cycD3、CDK4/cycD1、CDK6/cycD2的IC50分别为9、11、15 nM；靶向其他36种激酶的IC50为>10 μM）的口服活性且高度特异性的抑制剂，其可有效抑制Cdk4/6依赖性细胞Rb磷酸化过程（IC50 = 66 nM/pSer780 & 63 nM/pSer795； MDA-MB-435）。PF-00080665对Rb阳性的人乳腺癌/结肠癌/肺癌/白血病细胞具有选择性的抗增殖活性（IC50 = 40-400 nM；IC50 >3 μM/Rb阴性MDA-MB-468 & H2009），并且在体内显示出对小鼠多种晚期人类肿瘤异种移植物的有效（12.5-150 mg/kg/day p.o.）。
Preparation Note
该化学品可以溶液形式在-80°C保存6个月，-20°C下1个月（避光）。
signalword
Warning
hcodes
Hazard Classifications
Aquatic Chronic 2 - Muta. 2 - Repr. 2 - STOT RE 2 Oral
target_organs
Bone marrow,male reproductive organs
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Fiona J Ruiz et al.
Cancers, 13(18) (2021-09-29)
Cervical cancer tumors with undetectable HPV (HPVU) have been underappreciated in clinical decision making. In this study, two independent CC datasets were used to characterize the largest cohort of HPVU tumors to date (HPVU = 35, HPV+ = 430). Genomic
Xiaoyang Li et al.
Cell death & disease, 9(5), 446-446 (2018-04-20)
Synovial sarcoma is a highly aggressive but rare form of soft tissue malignancy that primarily affects the extremities of the arms or legs, for which current chemotherapeutic agents have not been proven to be very effective. The cyclin-dependent kinase 4/6-retinoblastoma
Max Heckler et al.
Cancer discovery, 11(10), 2564-2581 (2021-05-05)
CDK4/6 inhibitors are approved to treat breast cancer and are in trials for other malignancies. We examined CDK4/6 inhibition in mouse and human CD8+ T cells during early stages of activation. Mice receiving tumor-specific CD8+ T cells treated with CDK4/6
Shinya Kitamura et al.
Cancer science, 113(2), 802-807 (2021-12-07)
Extramammary Paget's disease (EMPD) is a rare adnexal neoplasm commonly seen in the genital areas among the senior population. The prognosis of advanced EMPD is not favorable; thus, the development of potential treatments has long been sought. Cyclin-dependent kinase (CDK)
Flora Doffe et al.
Cancers, 14(15) (2022-07-28)
The recent trend in 3D cell modeling has fostered the emergence of a wide range of models, addressing very distinct goals ranging from the fundamental exploration of cell-cell interactions to preclinical assays for personalized medicine. It is clear that no
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持